Literature DB >> 10436866

Pharmacology and safety of the leukotriene antagonists.

L J Smith1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10436866     DOI： 10.1007/BF02737604

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN： 1080-0549            Impact factor:   8.667


× No keyword cloud information.
  47 in total

1.  Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist.

Authors:  J Grossman; I Faiferman; J W Dubb; D J Tompson; W Busse; E Bronsky; A Montanaro; L Southern; D Tinkelman
Journal:  J Asthma       Date:  1997       Impact factor: 2.515

2.  Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist.

Authors:  J P Finnerty; R Wood-Baker; H Thomson; S T Holgate
Journal:  Am Rev Respir Dis       Date:  1992-04

3.  Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma.

Authors:  S R Findlay; J M Barden; C B Easley; M Glass
Journal:  J Allergy Clin Immunol       Date:  1992-05       Impact factor: 10.793

4.  Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group.

Authors:  B Knorr; J Matz; J A Bernstein; H Nguyen; B C Seidenberg; T F Reiss; A Becker
Journal:  JAMA       Date:  1998-04-15       Impact factor: 56.272

5.  Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist.

Authors:  P J Manning; R M Watson; D J Margolskee; V C Williams; J I Schwartz; P M O'Byrne
Journal:  N Engl J Med       Date:  1990-12-20       Impact factor: 91.245

6.  Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.

Authors:  B Dahlén; E Nizankowska; A Szczeklik; O Zetterström; G Bochenek; M Kumlin; L Mastalerz; G Pinis; L J Swanson; T I Boodhoo; S Wright; L M Dubé; S E Dahlén
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

7.  The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma.

Authors:  S C Lazarus; H H Wong; M J Watts; H A Boushey; B J Lavins; M C Minkwitz
Journal:  Am J Respir Crit Care Med       Date:  1997-12       Impact factor: 21.405

8.  Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval.

Authors:  E A Bronsky; J P Kemp; J Zhang; D Guerreiro; T F Reiss
Journal:  Clin Pharmacol Ther       Date:  1997-11       Impact factor: 6.875

9.  The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics.

Authors:  B Dahlén; M Kumlin; D J Margolskee; C Larsson; H Blomqvist; V C Williams; O Zetterström; S E Dahlén
Journal:  Eur Respir J       Date:  1993-07       Impact factor: 16.671

10.  Effect of RG 12525, a new leukotriene antagonist, on pulmonary function of asthmatic adults.

Authors:  M J Welch; H S Nelson; B R Paull; J A Smith; G Feiss; R E Tobey
Journal:  Ann Allergy       Date:  1994-04
View more
  3 in total

Review 1.  Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis.

Authors:  Bengü Cobanoğlu; Elina Toskala; Ahmet Ural; Cemal Cingi
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

2.  The linkage between Churg-Strauss syndrome and leukotriene receptor antagonists: fact or fiction?

Authors:  Deanna L McDanel; Barbara A Muller
Journal:  Ther Clin Risk Manag       Date:  2005-06       Impact factor: 2.423

Review 3.  Is Leukotriene Receptor Antagonist the Direct Cause of Churg-Strauss Syndrome in Asthmatic Patients?

Authors:  Salomi Paul; Shreyas Yakkali; Sneha Teresa Selvin; Sonu Thomas; Viktoriya Bikeyeva; Ahmed Abdullah; Aleksandra Radivojevic; Anas A Abu Jad; Anvesh Ravanavena; Chetna Ravindra; Emmanuelar O Igweonu-Nwakile; Safina Ali; Pousette Hamid
Journal:  Cureus       Date:  2022-08-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.